Hospital Ramón y Cajal -ko ikertzaileekin lankidetzan egindako argitalpenak (49)

2024

  1. Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study

    Multiple Sclerosis and Related Disorders, Vol. 90

  2. Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

    Neurologia, Vol. 39, Núm. 5, pp. 383-391

  3. Value contribution of blood-based neurofilament light chain as a biomarker in multiple sclerosis using multi-criteria decision analysis

    Frontiers in Public Health, Vol. 12

  4. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (I)

    Revista de neurologia, Vol. 79, Núm. 1, pp. 21-29

  5. XVI Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2023 (II)

    Revista de neurologia, Vol. 79, Núm. 2, pp. 51-66

2023

  1. Aluminum alters excitability by inhibiting calcium, sodium, and potassium currents in bovine chromaffin cells

    Journal of Neurochemistry, Vol. 165, Núm. 2, pp. 162-176

  2. Monitoring response to disease-modifying treatment in multiple sclerosis

    Neurology Perspectives, Vol. 3, Núm. 2

  3. Non-Excitatory Amino Acids, Melatonin, and Free Radicals: Examining the Role in Stroke and Aging

    Antioxidants, Vol. 12, Núm. 10

  4. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)

    Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30

  5. XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)

    Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60

2022

  1. Consensus on early detection of disease progression in patients with multiple sclerosis

    Frontiers in Neurology, Vol. 13

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

  3. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology

    Multiple Sclerosis and Related Disorders, Vol. 63

  4. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells

    Frontiers in Immunology, Vol. 12

2021

  1. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry

    PLoS ONE, Vol. 16, Núm. 10 October

  2. Recommendations for vaccination in patients with multiple sclerosis who are eligible for immunosuppressive therapies: Spanish consensus statement

    Neurologia, Vol. 36, Núm. 1, pp. 50-60

  3. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)

    Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406

  4. XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)

    Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442

2020

  1. Micromolar concentrations of Zn2+ depress cellular excitability through a blockade of calcium current in rat adrenal slices

    Toxicology, Vol. 444

  2. XII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2019 (I)

    Revista de neurologia, Vol. 70, Núm. 10, pp. 379-390